(2S)-1-(3,4-dimethylphenoxy)-3-[4-(2-hydroxyethyl)piperazin-1-yl]propan-2-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (2S)-1-(3,4-dimethylphenoxy)-3-[4-(2-hydroxyethyl)piperazin-1-yl]propan-2-ol
• 化学式: C₁₇H₂₈N₂O₃
• 分子量: 308.4
• InChiKey: CPEUMMZDNSCLSL-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  56.2
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Substituted benzoxazepine for cancer therapy
  申请人：University of Cape Town

  公开号：US10220033B2

  公开（公告）日：2019-03-05

  Implementations of the present invention include a compound and methods for inhibiting karyopherin beta 1 activity by administering to a patient in need thereof a therapeutically effective amount of a substituted benzoxazepine. The compound of Formula II, 9-[(1-methylpiperidin-3-yl)methoxy]-4-[(6-methylpyridin-2-yl)methyl]-7-(5-methylthiophen-2-yl)-3,5-dihydro-2H-1,4-benzoxazepine or one of its salts, inhibits the import of protein and transcription factors, such as NFAT and P65/NFKB into the nucleus of a cell, and thus has anti-cancer effects enabling the compound to be used for cancer treatment.

  本发明的实施方案包括一种通过向有需要的患者施用治疗有效量的取代苯并氧氮杂卓来抑制核仁素β1活性的化合物和方法。式II化合物，9-[(1-甲基哌啶-3-基)甲氧基]-4-[(6-甲基吡啶-2-基)甲基]-7-(5-甲基噻吩-2-基)-3,5-二氢-2H-1,4-苯并氧氮杂卓或其盐之一，可抑制蛋白质和转录因子，如NFAT和P65/NFKB导入细胞核，从而具有抗癌作用，使该化合物可用于癌症治疗。
• SMALL MOLECULE INHIBITORS FOR CANCER THERAPY
  申请人：University of Cape Town

  公开号：US20170216285A1

  公开（公告）日：2017-08-03

  Compounds, including quinoxaline derivatives of Formula (I), for use in the treatment of cancer are described. In general, the compounds inhibit the import of proteins and transcription factors such as Kpnα, AP-1, P65, NFAT into the nucleus of a cell by inhibiting the nuclear import protein, Kpnβ1. Cancer cells have elevated levels of Kpnβ1 and the inhibition of their nuclear import activity induces cell apoptosis. The administration of an effective amount of any one of the compounds results in cell apoptosis in cancer cells, whilst non-cancer cells are substantially unaffected by the inhibition of Kpnβ1's nuclear import activity.
• SUBSTITUTED BENZOXAZEPINE FOR CANCER THERAPY
  申请人：University of Cape Town

  公开号：US20180221368A1

  公开（公告）日：2018-08-09

  Implementations of the present invention include a compound and methods for inhibiting karyopherin beta 1 activity by administering to a patient in need thereof a therapeutically effective amount of a substituted benzoxazepine. The compound of Formula II, 9-[(1-methylpiperidin-3-yl)methoxy]-4-[(6-methylpyridin-2-yl)methyl]-7-(5-methylthiophen-2-yl)-3,5-dihydro-2H-1,4-benzoxazepine or one of its salts, inhibits the import of protein and transcription factors, such as NFAT and P65/NFKB into the nucleus of a cell, and thus has anti-cancer effects enabling the compound to be used for cancer treatment.
• US9931339B2
  申请人：——

  公开号：US9931339B2

  公开（公告）日：2018-04-03